Claims for Patent: 8,278,109

Summary for Patent: 8,278,109

Title:	Hyperglycosylated hCG detection device
Abstract:	The present invention related to a pregnancy test device that can selectively detect hyperglycosylated human chorionic gonadotropin (hCG-H) in a liquid sample. The sample can be deposited on a proximal portion of the device for transport to a distal portion of the device. The device can include a release medium formed of a first material and including a detectable label thereon and a capture medium, including a capture site, in fluid communication with the release medium and formed of a second, different material. At least one of the release medium and the capture medium includes a binding member that exhibits a moderate to high affinity for hCG-H and is selectively or preferentially reactive with hCG-H.
Inventor(s):	Nazareth; Albert R. (Mercerville, NJ), Snowden; Timothy (Howell, NJ)
Assignee:	Church & Dwight Co., Inc. (Princeton, NJ)
Application Number:	12/704,892
Patent Claims:	1. A device for selectively detecting hyperglycosylated human chorionic gonadotropin (hCG-H) in a liquid sample deposited directly or indirectly on a proximal portion of the device for transport to a distal portion of the device, wherein the device comprises: A) a release medium formed of a first material and comprising a labeled conjugate with a detectable label and a first binding member that is reactive with at least one of an epitope of hCG-H or an epitope of human chorionic gonadotropin (hCG); and B) a capture medium in fluid communication with the release medium and formed of a second, different material, the capture medium comprising a capture site that comprises a second binding member immobilized on the capture medium, said second binding member being reactive with at least one of an epitope of hCG-H or an epitope of hCG; wherein at least one of the release medium and the capture medium comprises a binding member that exhibits a moderate to high affinity for hCG-H and is selectively or preferentially reactive with hCG-H, and wherein it is only the second binding member that exhibits the moderate to high affinity for hCG-H and is selectively or preferentially reactive with hCG-H. 2. A method of evaluating the viability of a pregnancy, the method comprising: A) providing a test device comprising the device of claim 1; B) applying to the device a liquid sample potentially including one or both of regular hCG and hCG-H; and C) detecting the presence or lack thereof of hCG-H in the liquid sample, wherein the detected presence of hCG-H indicates a high probability of successful implantation and therefore a viable pregnancy. 3. A device for selectively detecting hyperglycosylated human chorionic gonadotropin (hCG-H) in a liquid sample deposited directly or indirectly on a proximal portion of the device for transport to a distal portion of the device, wherein the device comprises: A) a release medium formed of a first material and comprising a detectable label; B) a capture medium in fluid communication with the release medium and formed of a second, different material, the capture medium comprising a capture site; and C) a scavenger component that is selectively or preferentially reactive with regular hCG, the scavenger component being located between a location of sample deposit and the capture site; wherein at least one of the release medium and the capture medium comprises a binding member that is reactive with hCG-H. 4. The device of claim 3, wherein: A) the release medium comprises a labeled conjugate comprising the detectable label and a first binding member that is reactive with a first epitope of hCG-H; and B) the capture medium comprises a capture site comprising a second binding member that is reactive with a second epitope of hCG-H. 5. The device of claim 4, wherein at least one of the first binding member and the second binding member exhibits a moderate to high affinity for hCG-H and is selectively or preferentially reactive with hCG-H. 6. The device of claim 4, wherein the scavenger component is located downstream from the sample deposit and up to and including a region including the labeled conjugate. 7. The device of claim 4, wherein the scavenger component is located between a region including the labeled conjugate and a region including the capture site. 8. The device of claim 4, wherein the scavenger component is located at any region on the capture medium upstream from the capture site. 9. The device of claim 4, wherein: A) the release medium comprises: i) the detectable label and a first binding member reactive with a first epitope of hCG-H; and ii) a capturable component comprising a second binding member reactive with a second epitope of hCG-H, such that in the presence of hCG-H in the sample, a complex is formed comprising the labeled conjugate, hCG-H, and the capturable component; and B) the capture medium comprises a capture site having immobilized thereon a capture component having a binding affinity for the capturable component. 10. The device of claim 9, wherein the capturable component comprises a biotinylated capturable component and the capture component comprises streptavidin. 11. The device of claim 9, wherein at least one of the first binding member and the second binding member exhibits a moderate to high affinity for hCG-H and is selectively or preferentially reactive with hCG-H. 12. The device of claim 9, wherein the scavenger component is located downstream from the sample deposit and up to and including a region including the labeled conjugate. 13. The device of claim 9, wherein the scavenger component is located between a region including the labeled conjugate and a region including the capture site. 14. The device of claim 9, wherein the scavenger component is located at any region on the capture medium upstream from the capture site. 15. A method of evaluating the viability of a pregnancy, the method comprising: A) providing a test device comprising the device of claim 3; B) applying to the device a liquid sample potentially including one or both of regular hCG and hCG-H; and C) detecting the presence or lack thereof of hCG-H in the liquid sample, wherein the detected presence of hCG-H indicates a high probability of successful implantation and therefore a viable pregnancy. 16. A device for selectively detecting hyperglycosylated human chorionic gonadotropin (hCG-H) in a liquid sample deposited directly or indirectly on a proximal portion of the device for transport to a distal portion of the device, wherein the device comprises: A) a release medium formed of a first material and comprising: (i) a first group of labeled conjugates comprising a detectable label and a binding member that is selectively or preferentially reactive with an epitope of regular hCG; and (ii) a second group of labeled conjugates comprising a detectable label and a binding member is selectively or preferentially reactive with an epitope of hCG-H and exhibits a moderate to high affinity for hCG-H; and B) a capture medium in fluid communication with the release medium and formed of a second, different material, the capture medium comprising a capture site having immobilized thereon at least one group of binding members; wherein the binding members that are selectively or preferentially reactive with hCG-H comprise greater than 50% of the total number of binding members present on the release medium. 17. The device of claim 16, wherein the first and second groups of labeled conjugates are provided as a mixture. 18. The device of claim 16, wherein the first group of labeled conjugates is located at a different location on the release medium than the second group of labeled conjugates. 19. A method of evaluating the viability of a pregnancy, the method comprising: A) providing a test device comprising the device of claim 16; B) applying to the device a liquid sample potentially including one or both of regular hCG and hCG-H; and C) detecting the presence or lack thereof of hCG-H in the liquid sample, wherein the detected presence of hCG-H indicates a high probability of successful implantation and therefore a viable pregnancy. 20. A device for selectively detecting hyperglycosylated human chorionic gonadotropin (hCG-H) in a liquid sample deposited on a proximal portion of the device for transport to a distal portion of the device, wherein the device comprises: A) a release medium formed of a first material and comprising a detectable label; B) at least one binding member that exhibits a moderate to high affinity for hCG-H and is selectively or preferentially reactive with an epitope of hCG-H; C) at least one binding member that is reactive with an epitope of regular hCG; and D) a capture medium in fluid communication with the release medium and formed of a second, different material, the capture medium comprising: (i) a first capture site that binds hCG-H; and (ii) a second capture site that binds regular hCG. 21. The device of claim 20, wherein the at least one binding member reactive with an epitope of regular hCG is selectively or preferentially reactive with an epitope of regular hCG. 22. The device of claim 20, wherein: A) the release medium comprises: i) a labeled conjugate comprising a detectable label and ii) at least one binding member that is reactive with a epitope common to regular hCG and hCG-H; and B) the capture medium comprises: i) a capture site comprising a binding member that is reactive with a second epitope of hCG-H; and ii) a capture site comprising a binding member that is reactive with a second epitope of regular hCG; wherein at least one of the binding members reactive with an epitope of hCG-H exhibits a moderate to high affinity for hCG-H and is selectively or preferentially reactive with hCG-H. 23. The device of claim 22, wherein at least one of the binding members reactive with an epitope of regular hCG is selectively or preferentially reactive with an epitope of regular hCG. 24. The device of claim 20, wherein A) the release medium comprises: i) a labeled conjugate comprising a detectable label and at least one binding member reactive with an epitope common to regular hCG and hCG-H; and ii) a capturable component comprising a binding member that exhibits a moderate to high affinity for hCG-H and is selectively or preferentially reactive with a second epitope of hCG-H; and B) the capture medium comprises: i) a first capture site having immobilized thereon a capture component having a binding affinity for the capturable component; and ii) a second capture site comprising an immobilized binding member that is reactive with a second epitope of hCG. 25. The device of claim 24, wherein the capturable component comprises a biotinylated capturable component and the capture component comprises streptavidin. 26. The device of claim 20, wherein A) the release medium comprises: i) a labeled conjugate comprising a detectable label and at least one binding member reactive with an epitope common to regular hCG and hCG-H; and ii) a capturable component comprising a binding member that is selectively or preferentially reactive with a second epitope of regular hCG; and B) the capture medium comprises: i) a first capture site having immobilized thereon a capture component having a binding affinity for the capturable component; and ii) a second capture site comprising an immobilized binding member that exhibits a moderate to high affinity for hCG-H and is selectively or preferentially reactive with a second epitope of hCG-H. 27. The device of claim 26, wherein the capturable component comprises a biotinylated capturable component and the capture component comprises streptavidin. 28. A method of evaluating the viability of a pregnancy, the method comprising: A) providing a test device comprising the device of claim 20; B) applying to the device a liquid sample potentially including one or both of regular hCG and hCG-H; and C) detecting the presence or lack thereof of hCG-H in the liquid sample, wherein the detected presence of hCG-H indicates a high probability of successful implantation and therefore a viable pregnancy. 29. A device for selectively detecting hyperglycosylated human chorionic gonadotropin (hCG-H) in a liquid sample, the device comprising: A) a common fluid path for receiving and distributing the liquid sample; B) at least one release medium in fluid communication with the common fluid path, the at least one release medium being formed of a first material and comprising a detectable label; C) a first capture medium in fluid communication with the at least one release medium and formed of a second material, the first capture medium comprising a capture site that directly or indirectly selectively or preferentially binds hCG-H; and D) a second capture medium in fluid communication with the at least one release medium and formed of the second material, the second capture medium comprising a capture site that directly or indirectly binds regular hCG. 30. The device of claim 29, wherein: A) the at least one release medium comprises: i) a first release medium comprising a labeled conjugate comprising a detectable label and a binding member that is reactive with a first epitope of hCG-H; and ii) a second release medium comprising a labeled conjugate comprising a detectable label and a binding member that is reactive with a first epitope of regular hCG; B) the first capture medium being in fluid communication with the first release medium, the first capture medium comprising a capture site comprising a binding member that exhibits a moderate to high affinity for hCG-H and is selectively or preferentially reactive with a second epitope of hCG-H; and C) the second capture medium being in fluid communication with the second release medium, the second capture medium comprising a capture site comprising a binding member that is selectively or preferentially reactive with a second epitope of regular hCG. 31. The device of claim 29, wherein: A) the at least one release medium comprises: i) a first release medium comprising a labeled conjugate comprising a detectable label and a binding member that is reactive with a first epitope of hCG-H, and further comprising a capturable component comprising a binding member that exhibits a moderate to high affinity for hCG-H and is selectively or preferentially reactive with a second epitope of hCG-H; and ii) a second release medium comprising a labeled conjugate comprising a detectable label and a binding member that is reactive with a first epitope of regular hCG; B) the first capture medium being in fluid communication with the first release medium, the first capture medium comprising a capture site having immobilized thereon a capture component having a binding affinity for the capturable component; and C) the second capture medium being in fluid communication with the second release medium, the second capture medium comprising a capture site comprising a binding member that is reactive with a second epitope of regular hCG. 32. The device of claim 31, wherein the capturable component comprises a biotinylated capturable component and the capture component comprises streptavidin. 33. The device of claim 29, comprising a single release medium in fluid communication with both the first capture medium and the second capture medium, the release medium comprising a labeled conjugate comprising a detectable label and a binding member that is reactive with a first epitope of hCG-H and a first epitope of regular hCG. 34. The device of claim 29, wherein the first capture medium comprises a capture site comprising a binding member that exhibits a moderate to high affinity for hCG-H and is selectively or preferentially reactive with a second epitope of hCG-H; and the second capture medium comprises a capture site comprising a binding member that is reactive with a second epitope of regular hCG. 35. A method of evaluating the viability of a pregnancy, the method comprising: A) providing a test device comprising the device of claim 29; B) applying to the device a liquid sample potentially including one or both of regular hCG and hCG-H; and C) detecting the presence or lack thereof of hCG-H in the liquid sample, wherein the detected presence of hCG-H indicates a high probability of successful implantation and therefore a viable pregnancy.

Details for Patent 8,278,109

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	January 15, 1974	8,278,109	2030-02-12
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	December 27, 1984	8,278,109	2030-02-12
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 15, 1985	8,278,109	2030-02-12
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 16, 1990	8,278,109	2030-02-12
Bel-mar Laboratories, Inc.	CHORIONIC GONADOTROPIN	chorionic gonadotropin	Injection	017054	March 26, 1974	8,278,109	2030-02-12